Bridge Biotherapeutics
Business Services · 11-50 Employees
View Company Info for Free
Overview
Website
www.bridgebiorx.comRevenue
$6.7 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
2
1
1
1
About Bridge Biotherapeutics
Bridge Biotherapeutics Inc. is a publicly traded clinical-stage biotech company based in the Republic of Korea with offices in the U.S. and China. Founded in 2015, Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics for disease indications with high unmet medical needs including cancer, ulcerative colitis, and fibrotic diseases. The company's clinical pipeline includes BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis; BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF); and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations. Entering 2022, the company enhances its strategic focus on fibrotic diseases and cancers.Explore more
Bridge Biotherapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bridge Biotherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Bridge Biotherapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Bridge Biotherapeutics
Product Launch: Get notified when Bridge Biotherapeutics launches new products
Funding: Get notified immidiatlly once Bridge Biotherapeutics has new funding data
Website visits: Recent activity has been detected on your website
Check out if Bridge Biotherapeutics is spiking on competitors!
Bridge Biotherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Bridge Biotherapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Bridge Biotherapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Bridge Biotherapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Bridge Biotherapeutics
Compare insights from companies similar to Bridge Biotherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Bridge Biotherapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Bridge Biotherapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Bridge Biotherapeutics.
Bridge Biotherapeutics Tech Stack
A closer look at the technologies used by Bridge Biotherapeutics
Bridge Biotherapeutics News & Media
Bridge Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SEONGNAM, South Korea and BOSTON, Dec. 30, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis and cancer, today announced that James Jungkue Lee, Founder and CEO of Bridge Biotherapeutics, will...Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program
Bridge Biotherapeutics Enters into a joint research agreement with the Chinese drug discovery platform company "HitGen" to accelerate the discovery of new drug candidates for a FIC novel cancer therapeutics program Aims to strengthen its oncology portfolio with a novel drug candidate for newly identified hits from HitGen's proprietary DEL that are expected to exhibit potent anticancer activity CHENGDU, China, Aug. 22, 2024 /PRNewswire/ -- Bridge Biotherapeutics ("Bridge", KQ288330), a clinical-sBridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program
Bridge Biotherapeutics Enters into a joint research agreement with the Chinese drug discovery platform company "HitGen" to accelerate the discovery of new drug candidates for a FIC novel cancer therapeutics program Aims to strengthen its oncology portfolio with a novel drug candidate for...Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis
SEONGNAM, South Korea, July 30, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis and cancer, today announced that patient participant enrollment has been completed in the Phase 2 clinical study of BBT-877, a novel autotoxin (ATX) inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). The Phase 2, multi-center, randomized, double-blind, placebo-controlled study (NCT05483907) aims to evalu
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Bridge Biotherapeutics
Sign Up For FreeTo access detailed company insights
Bridge Biotherapeutics Inc. is a publicly traded clinical-stage biotech company based in the Republic of Korea with offices in the U.S. and China. Founded in 2015, Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics for disease indications with high unmet medical needs including cancer, ulcerative colitis, and f... Read More
